Literature DB >> 2120396

Cholesterol uptake by human glioma cells via receptor-mediated endocytosis of low-density lipoprotein.

M Murakami1, Y Ushio, Y Mihara, J Kuratsu, S Horiuchi, Y Morino.   

Abstract

Low-density lipoprotein (LDL) is a carrier of the cholesterol found in human plasma. Cells utilize cholesterol for membrane synthesis by taking up LDL via receptor-mediated endocytosis. In the present study, interactions of LDL with human malignant glioma cell lines (U-251 MG and KMG-5) were investigated biochemically and morphologically. The LDL, labeled with the fluorescent dyes 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine (DiI) and fluorescein isothiocyanate (FITC), was internalized by both cell processes and cell bodies. Reductive methylation of DiI-labeled LDL, which abolishes the ability of the cell to bind to the LDL receptor, prevented the internalization of the cholesterol moiety of LDL. Cellular binding of 125I-LDL to U-251 MG cells at 4 degrees C revealed the presence of a specific saturable-associated receptor (dissociation constant (Kd) approximately 38 micrograms/ml). Endocytic uptake of 125I-LDL or 3H-cholesterol oleate-labeled LDL (3H-LDL) at 37 degrees C demonstrated the cell-associated 125I-LDL and 3H-LDL increase. The intracellular degradation of protein moiety increased linearly with time. Reductive methylation of 3H-LDL led to a remarkable decrease in the cell-associated cholesterol moiety of LDL. The difference in uptake of the cholesterol moiety of LDL between U-251MG cells and KMG-5 cells showed that the U-251MG cells, which proliferate more actively than KMG-5 cells, take up more of the cholesterol moiety of LDL than do the KMG-5 cells. Thus, LDL cholesterol seems to be endocytosed predominantly via the LDL receptor present on the plasma membrane of malignant glioma cells. In addition, for growth, these cells may require large amounts of the cholesterol moiety of LDL.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120396     DOI: 10.3171/jns.1990.73.5.0760

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

1.  Serum cholesterol in cerebral malignancies.

Authors:  P Grieb; M S Ryba; J Jagielski; W Gackowski; P Paczkowski; S J Chrapusta
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Low density lipoproteins and Lovastatin modulate the organ-specific transendothelial migration of primary and metastatic human colon adenocarcinoma cell lines in vitro.

Authors:  N Mehta; J Hordines; D Sykes; R J Doerr; S A Cohen
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

3.  Low density lipoprotein receptors and polyamine levels in human colorectal adenocarcinoma.

Authors:  M Notarnicola; M Linsalata; M G Caruso; A Cavallini; A Di Leo
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

Review 4.  Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets.

Authors:  Junfeng Bi; Sudhir Chowdhry; Sihan Wu; Wenjing Zhang; Kenta Masui; Paul S Mischel
Journal:  Nat Rev Cancer       Date:  2019-12-05       Impact factor: 69.800

5.  A chemical biology approach reveals a dependency of glioblastoma on biotin distribution.

Authors:  Jeehyun Yoon; Oleg V Grinchuk; Srinivasaraghavan Kannan; Melgious Jin Yan Ang; Zhenglin Li; Emmy Xue Yun Tay; Ker Zhing Lok; Bernice Woon Li Lee; You Heng Chuah; Kimberly Chia; Roberto Tirado Magallanes; Chenfei Liu; Haonan Zhao; Jin Hui Hor; Jhin Jieh Lim; Touati Benoukraf; Tan Boon Toh; Edward Kai-Hua Chow; Jean-Paul Kovalik; Jianhong Ching; Shi-Yan Ng; Ming Joo Koh; Xiaogang Liu; Chandra Shekhar Verma; Derrick Sek Tong Ong
Journal:  Sci Adv       Date:  2021-09-03       Impact factor: 14.136

6.  Accumulation of 99mTc-low-density lipoprotein in human malignant glioma.

Authors:  J Leppälä; M Kallio; T Nikula; P Nikkinen; K Liewendahl; J Jääskeläinen; S Savolainen; H Gylling; J Hiltunen; J Callaway
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.